 Home > Active Ingredient News > Antitumor Therapy > Eur Heart J: BBs and ACEI/ARBs are used to prevent left ventricular dysfunction caused by anthracyclines or trastuzumab in breast cancer patients

Eur Heart J: BBs and ACEI/ARBs are used to prevent left ventricular dysfunction caused by anthracyclines or trastuzumab in breast cancer patients

 Last Update: 2022-01-08
 Source: Internet
 Author: User

Tags

blank journal template

tgf beta 1

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Trastuzumab and anthracyclines, which are often used to treat breast cancer , may impair myocardial function and reduce the left ventricular ejection fraction (LVEF), which may lead to heart failure
.

Randomized controlled trials (the RCT) evaluated the β-blockers (BB), vascular angiotensin receptor blocker (ARB) and an angiotensin converting enzyme inhibitor (ACEI) of trastuzumab and anthracyclines The effect of drug-related cardiotoxicity

Breast cancer blood vessels

Recently, Eur Heart J, an authoritative journal in the cardiovascular field, published a research article in which researchers reported the results of a meta-analysis of RCTs carried out in breast cancer patients
.

The main analysis of this study is to clarify the effect of BBs and ACEI/ARBs on LVEF in patients receiving trastuzumab or anthracycline therapy
.

The researchers performed a secondary analysis of the effects of BBs or ACEI/ARBs on LVEF in patients receiving trastuzumab and anthracyclines

A total of nine RCTs (n=1362) were included in the meta-analysis
.

All patients are female

It can be seen that during trastuzumab and anthracycline-containing drugs, compared with placebo, taking BB and ACEI/ARB treatments are both associated with maintaining LVEF, indicating that both are beneficial to the heart
.

During trastuzumab and anthracycline-containing treatments, compared with placebo, taking BB and ACEI/ARB treatments were both associated with maintaining LVEF, indicating that both are beneficial to the heart
.

Original source:

Christian Lewinter,et al.

A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.